Convergen Pharmaceuticals
Latest round
- Seed
Last raised
- Dec 2025
Total raised
- $10M
Investors
- 4
About Convergen Pharmaceuticals
, trading under the name Convergen, provides targeted protein degradation therapies for the healthcare industry. The firm was established to address unmet medical needs in the field of neurodegenerative diseases. The company works with large pharmaceutical companies and medical research institutions to provide innovative protein degradation technologies and drug pipelines. Product offerings include the proprietary TrimTAC platform, which utilizes the E3 ubiquitin ligase TRIM21 to specifically recognize and selectively clear pathogenic multimeric protein aggregates in neurodegenerative diseases such as Alzheimer's and Parkinson's, while preserving the function of normal monomeric proteins. The company generates revenue from licensing its TrimTAC platform technology and early drug pipelines to large pharmaceutical companies.
Who invested in Convergen Pharmaceuticals
4 investors across 2 rounds
See all investors in Convergen Pharmaceuticals
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Convergen Pharmaceuticals
Who invested in Convergen Pharmaceuticals?
Convergen Pharmaceuticals has 4 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Convergen Pharmaceuticals raised?
Convergen Pharmaceuticals has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did Convergen Pharmaceuticals last raise money?
Convergen Pharmaceuticals's most recent round on record is a Seed, in Dec 2025.
What does Convergen Pharmaceuticals do?
, trading under the name Convergen, provides targeted protein degradation therapies for the healthcare industry.
Where is Convergen Pharmaceuticals headquartered?
Convergen Pharmaceuticals is headquartered in Suzhou, China.
Which VCs invest in companies like Convergen Pharmaceuticals?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Peak XV Partners, MPCi and Luminous Ventures back biotechnology companies at Convergen Pharmaceuticals's stage. Their profiles are linked below.
VCs backing biotechnology startups at Seed
Raising like Convergen Pharmaceuticals? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.